Selective activation of NFAT by promyelocytic leukemia protein

Oncogene

Volumn 27, Issue 27, 2008, Pages 3821-3830

  Lo, Y H ^a,b   Wu, C C ^b   Shih, H M ^c   Lai, M Z ^a,b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CBP; NFAT; PML; Transcription activation; Tumor suppressor

Indexed keywords

ISOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN I; PROMYELOCYTIC LEUKEMIA PROTEIN IV; PROMYELOCYTIC LEUKEMIA PROTEIN VI; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DETERMINATION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

CHLORAMPHENICOL O-ACETYLTRANSFERASE; CHROMATIN; HUMANS; JURKAT CELLS; KINETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 45549087530     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.2     Document Type: Article

References (40)

1. Avots A, Buttmann M, Chuvpilo S, Escher C, Smola U, Bannister AJ et al. (1999). CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Immunity 10: 515-524.
2. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. (2002). Deconstructing PML-induced premature senescence. EMBO J 21: 3358-3369.
3. Bruno S, Ghiotto F, Fais F, Fagioli M, Luzi L, Pelicci PG et al. (2003). The PML gene is not involved in the regulation of MHC class I expression in human cell lines. Blood 101: 3514-3519.
4. Buschbeck M, Uribesalgo I, Ledl A, Gutierrez A, Minucci S, Muller S et al. (2007). PML4 induces differentiation by Myc destabilization. Oncogene 26: 3415-3422.
5. Cairo S, De Falco F, Pizzo M, Salomoni P, Pandolfi PP, Meroni G. (2005). PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts. Oncogene 24: 2195-2203.
6. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A et al. (2006). Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 66: 6192-6198.
7. Crabtree GR, Olson EN. (2002). NF-AT signaling: choreographing the social lives of cells. Cell 109: S67-S79.
8. Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. (2005). PML mediates IFN-α-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105: 1280-1287.
9. Dellaire G, Bazett-Jones DP. (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26: 963-977.
10. Doucas V, Tini M, Egan DA, Evans RM. (1999). Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc Natl Acad Sci USA 96: 2627-2632.
11. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K et al. (2000). Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195.
12. Garcia-Rodriguez C, Rao A. (1998). Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein. J Exp Med 187: 2031-2036.
13. Goddard AD, Yuan JQ, Fairbarin L, Dexter M, Borrow J, Kozak C et al. (1995). Cloning of the murine homolog of the leukemia-associated PML gene. Mamm Genome 6: 732-737.
14. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W et al. (2000). The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
15. Ho HY, Lee HH, Lai MZ. (1997). Overexpression of mitogen-activated protein kinase kinase kinase reversed cAMP inhibition of NF-κB in T cells. Eur J Immunol 27: 222-226.
16. Hogan PG, Chen L, Nardone J, Rao A. (2003). Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17: 2205-2232.
17. Ishov AM, Vladimirova OV, Maul GG. (2004). Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. J Cell Sci 117: 3807-3820.
18. Jensen K, Shiels C, Freemont PS. (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233.
19. Latinis KM, Norian LA, Eliason SL, Koretzky GA. (1997). Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J Biol Chem 272: 31427-31434.
20. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ et al. (2000). Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol 20: 1784-1796.
21. Lin DY, Fang HI, Ma AH, Huang YS, Pu YS, Jenster G et al. (2004). Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 24: 10529-10541.
22. Lin DY, Lai MZ, Ann DK, Shih HM. (2003). Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem 278: 15958-15965.
23. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. (2002). Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109: 719-731.
24. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M et al. (2003). Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115: 751-763.
25. Möller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Dröge W et al. (2003). PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63: 4310-4314.
26. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. (1997). Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275: 523-527.
27. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. (2005). The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 105: 3686-3690.
28. Salomoni P, Pandolfi PP. (2002). The role of PML in tumor suppression. Cell 108: 165-170.
29. Tsai EY, Yie J, Thanos D, Goldfeld AE. (1996). Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 16: 5232-5244.
30. von Mikecz A, Zhang S, Montminy M, Tan EM, Hemmerich P. (2000). CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J Cell Biol 150: 265-273.
31. Wang J, Shiels C, Sasieni P, Wu PJ, Islam SA, Freemont PS et al. (2004). Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. J Cell Biol 164: 515-526.
32. Wang Q, Ji Y, Wang X, Evers BM. (2000). Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276: 466-471.
33. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al. (1998). PML is essential for multiple apoptotic pathways. Nat Genet 20: 266-272.
34. Wu CC, Hsu SC, Shih HM, Lai MZ. (2003a). NFATc is a target of p38 mitogen activated protein kinase in T cells. Mol Cell Biol 23: 6442-6454.
35. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S et al. (2001). The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259-2268.
36. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, Chang KS. (2003b). Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-κB survival pathway. J Biol Chem 278: 12294-12304.
37. Wu WS, Xu ZX, Ran R, Meng F, Chang KS. (2002). Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions. Oncogene 21: 3925-3933.
38. Youn HD, Chatila TA, Liu JO. (2000). Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J 19: 4323-4331.
39. Zhong S, Salomoni P, Pandolfi PP. (2000). The transcriptional role of PML and the nuclear body. Nat Cell Biol 2: E85-E90.
40. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK. (2002). Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem 27: 6923-6928.